NO20021615L - Nöytralt kationisk lipid for levering av nukleinsyre og medikament - Google Patents

Nöytralt kationisk lipid for levering av nukleinsyre og medikament

Info

Publication number
NO20021615L
NO20021615L NO20021615A NO20021615A NO20021615L NO 20021615 L NO20021615 L NO 20021615L NO 20021615 A NO20021615 A NO 20021615A NO 20021615 A NO20021615 A NO 20021615A NO 20021615 L NO20021615 L NO 20021615L
Authority
NO
Norway
Prior art keywords
drug
delivery
nucleic acid
cationic lipid
sup
Prior art date
Application number
NO20021615A
Other languages
English (en)
Other versions
NO20021615D0 (no
Inventor
Shi Kun Huang
Samuel Zalipsky
Wei-Ming Zhang
Bei Jin
Yolanda Platon Quinn
Original Assignee
Alza Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alza Corp filed Critical Alza Corp
Publication of NO20021615D0 publication Critical patent/NO20021615D0/no
Publication of NO20021615L publication Critical patent/NO20021615L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]
    • Y10T428/2984—Microcapsule with fluid core [includes liposome]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
NO20021615A 1999-10-08 2002-04-05 Nöytralt kationisk lipid for levering av nukleinsyre og medikament NO20021615L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15869399P 1999-10-08 1999-10-08
PCT/US2000/027974 WO2001026629A2 (en) 1999-10-08 2000-10-10 Neutral-cationic lipid for nucleic acid and drug delivery

Publications (2)

Publication Number Publication Date
NO20021615D0 NO20021615D0 (no) 2002-04-05
NO20021615L true NO20021615L (no) 2002-04-05

Family

ID=22569279

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20021615A NO20021615L (no) 1999-10-08 2002-04-05 Nöytralt kationisk lipid for levering av nukleinsyre og medikament

Country Status (17)

Country Link
US (2) US6974589B1 (no)
EP (1) EP1223916B1 (no)
JP (1) JP2003511405A (no)
KR (1) KR100723852B1 (no)
CN (2) CN1915968A (no)
AT (1) ATE276744T1 (no)
AU (2) AU7868400A (no)
CA (1) CA2386164A1 (no)
DE (1) DE60014133T2 (no)
DK (1) DK1223916T3 (no)
ES (1) ES2226932T3 (no)
HU (1) HUP0203117A3 (no)
IL (1) IL148968A0 (no)
MX (1) MXPA02002899A (no)
NO (1) NO20021615L (no)
WO (2) WO2001026625A2 (no)
ZA (1) ZA200202726B (no)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7303760B2 (en) 1999-04-23 2007-12-04 Alza Corporation Method for treating multi-drug resistant tumors
US7238368B2 (en) * 1999-04-23 2007-07-03 Alza Corporation Releasable linkage and compositions containing same
CA2369595C (en) 1999-04-23 2010-10-05 Alza Corporation Conjugate having a cleavable linkage for use in a liposome
US20040197390A1 (en) * 2001-05-29 2004-10-07 Shi-Kun Huang Neutral-cationic lipid for systemic delivery of factor VIII gene
WO2001026625A2 (en) * 1999-10-08 2001-04-19 Alza Corp Neutral-cationic lipid for nucleic acid and drug delivery
DE10207177A1 (de) 2002-02-19 2003-09-04 Novosom Ag Fakultativ kationische Lipide
CN1968714B (zh) * 2004-05-05 2013-10-16 赛伦斯治疗公司 脂质、脂质复合物及其应用
EP1935434A1 (en) * 2006-12-19 2008-06-25 Novosom AG Construction and use of transfection enhancer elements
WO2008131163A1 (en) * 2007-04-20 2008-10-30 Enzon Pharmaceuticals, Inc. Enzymatic anticancer therapy
CN101475503B (zh) * 2008-12-15 2012-02-15 山东大学 一种新型阳离子类脂及其制备方法和应用
EP2532649B1 (en) * 2011-06-07 2015-04-08 Incella GmbH Amino lipids, their synthesis and uses thereof
CN111671918A (zh) 2011-06-08 2020-09-18 川斯勒佰尔公司 Mrna递送的脂质纳米颗粒组合物和方法
ES2836279T3 (es) * 2012-04-04 2021-06-24 Samyang Biopharmaceuticals Método de preparación de una composición para administrar un fármaco aniónico
CN105585598B (zh) * 2014-10-20 2019-02-19 湖南师范大学 甘露糖衍生物阳离子脂质体纳米颗粒的制备方法
BR112018007611A2 (pt) 2015-10-14 2018-10-23 Bio Path Holding Inc ácidos nucleicos p-etóxi para formulação lipossômica
CN107200841B (zh) * 2016-03-17 2019-02-01 华东师范大学 一种培化二酰甘油的合成方法
ES2928654T3 (es) 2016-09-16 2022-11-21 Bio Path Holdings Inc Terapia combinada con oligonucleótidos antisentido liposomales
AU2018254263B2 (en) * 2017-04-19 2022-07-14 Apa- Advanced Technologies Ltd. Fusogenic liposomes, compositions, kits and use thereof for treating cancer

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5395619A (en) 1993-03-03 1995-03-07 Liposome Technology, Inc. Lipid-polymer conjugates and liposomes
US5965434A (en) 1994-12-29 1999-10-12 Wolff; Jon A. Amphipathic PH sensitive compounds and delivery systems for delivering biologically active compounds
DE19521412A1 (de) * 1995-06-14 1996-12-19 Boehringer Mannheim Gmbh Neue kationische und polykationische Amphiphile, diese enthaltende Reagenzien und deren Verwendung
US5855911A (en) 1995-08-29 1999-01-05 Board Of Regents, The University Of Texas System Liposomal phosphodiester, phosphorothioate, and P-ethoxy oligonucleotides
US6056973A (en) * 1996-10-11 2000-05-02 Sequus Pharmaceuticals, Inc. Therapeutic liposome composition and method of preparation
TW520297B (en) 1996-10-11 2003-02-11 Sequus Pharm Inc Fusogenic liposome composition and method
WO2000030444A1 (en) 1998-11-25 2000-06-02 Vanderbilt University Cationic liposomes for gene transfer
WO2001026625A2 (en) * 1999-10-08 2001-04-19 Alza Corp Neutral-cationic lipid for nucleic acid and drug delivery

Also Published As

Publication number Publication date
WO2001026629A3 (en) 2002-05-10
AU8006400A (en) 2001-04-23
CN1915968A (zh) 2007-02-21
DE60014133T2 (de) 2005-02-03
ZA200202726B (en) 2003-06-25
HUP0203117A3 (en) 2005-06-28
WO2001026629A2 (en) 2001-04-19
WO2001026625A2 (en) 2001-04-19
JP2003511405A (ja) 2003-03-25
KR100723852B1 (ko) 2007-05-31
AU7868400A (en) 2001-04-23
CA2386164A1 (en) 2001-04-19
EP1223916A2 (en) 2002-07-24
MXPA02002899A (es) 2002-10-23
NO20021615D0 (no) 2002-04-05
AU778817B2 (en) 2004-12-23
ATE276744T1 (de) 2004-10-15
IL148968A0 (en) 2002-11-10
DK1223916T3 (da) 2005-01-31
US20050260261A1 (en) 2005-11-24
HUP0203117A2 (hu) 2003-01-28
CN1378536A (zh) 2002-11-06
KR20020063875A (ko) 2002-08-05
EP1223916B1 (en) 2004-09-22
DE60014133D1 (de) 2004-10-28
ES2226932T3 (es) 2005-04-01
US6974589B1 (en) 2005-12-13

Similar Documents

Publication Publication Date Title
NO20021615D0 (no) Nöytralt kationisk lipid for levering av nukleinsyre og medikament
HU9203304D0 (en) 3-benzylidene-1-carbamoyl-2-pyrrolidone analogues
EA199600104A1 (ru) Повышенная биодоступность биологически активных соединений при связывании с производными полипирролкарбоксамидонафталиновой кислоты
MXPA03000547A (es) Uso de derivados de amidas de acido valproico y de acido 2-valproenico, para el tratamiento de manias en trastornos bipolares.
TR200001239T2 (tr) Tiyazolidinediyon türevlerini hazırlama prosesi.
EP0335979A4 (en) Thienopyrimidine derivatives
GR3036570T3 (en) 6-Azaindole thromboxane synthase inhibitors.
UA66748C2 (en) Phenyl substituted 4-azasteroids fluroderivatives, methods for the preparation thereof (variants) and pharmaceutical composition based thereon
DK1826214T3 (da) Sammensætning omfattende ferrocen-derivater og brændstofsammensætning omfattende sådanne derivater
PE68299A1 (es) 1,2,3,4-tetrahidroisoquinolinas terapeuticas
BR9813923A (pt) N n - bis(sulfonil) hidrazinas úteis como agentes antineoplásicos
WO2003075928A3 (en) Stable pharmaceutical compositions
SE1214315T3 (no)
DK1165584T3 (da) 2'-substitueret RNA fremstilling
WO2001012642A3 (de) Nucleosidderivate und verfahren zu deren herstellung
GB2321459A (en) Synthesis of carboxylic acid derivatives
IT1276161B1 (it) Derivati dell'acido fosfonico ad attivita' inibitrice delle metallopeptidasi
NZ524330A (en) Substituted biphenyl derivatives, method for preparing same and pharmaceutical compositions containing same
FR2794122B1 (fr) Nouveaux antioxydants, procedes de preparation et utilisations
TW345579B (en) Cyanoethylmelamine derivatives and method for producing them
FR2550189B1 (fr) Nouveaux derives acetyleniques possedant une activite d'inhibiteurs d'enzyme, leur preparation et leur application comme medicament

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application